Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reprogreyes
- Development stage
- Unknown
- Lead developer
- Qurgen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Reprogreyes is a protein-based regenerative medicine candidate developed by Qurgen for the treatment of various eye diseases. Currently in Phase 2 clinical development, the therapy is part of Qurgen's pipeline focused on in vivo cellular reprogramming. Reprogreyes utilizes specific proteins to trigger regenerative processes within the eye, aiming to address the underlying causes of vision loss in degenerative ophthalmic conditions. By promoting the repair or functional restoration of ocular tissues, it represents a novel approach to treating diseases that currently have limited therapeutic options.
- Brand names
- Reprogreyes
Beyond the preview
Go deeper on Reprogreyes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reprogreyes.